Pfizer Pays $135M To Bow Out Of Marketing Deal

Law360, New York (November 13, 2007, 12:00 AM EST) -- Pfizer Inc. seems to have mended its fraying relationship with partner Nektar Therapeutics by agreeing to pay Nektar $135 million in order to bow out of a marketing agreement the two companies had over the diabetes drug Exubera.

The companies announced Tuesday that they have resolved all contractual issues in relation to Exubera with the one-time payment of $135 million putting to rest any remaining obligations Pfizer had to Nektar.

“This agreement demonstrates the industry leadership of Pfizer and the company’s desire to work with world-class...
To view the full article, register now.

Law360 UK

UK Financial Services

Read Our Latest UK Legal News & Analysis

Financial Services Law360 UK and Insurance Law360 UK provide breaking news and in-depth analysis on U.K. and European Union regulation, enforcement, legislation, and litigation involving banks, investment firms, insurers, and more.